Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy
- 361 Downloads
There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA.
We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, <0.5, 0.5–1, >1–2, or >2 mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS).
Among all margins, PM clearance up to 2 mm was prognostic of DFS (p = 0.01) and OS (p = 0.01). Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048–0.881, p = 0.033), DFS (HR 0.46, 95% CI 0.22–0.96, p = 0.03), and OS (HR 0.31, 95% CI 0.14–0.74, p = 0.008). A margin status of >2 mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11–0.89, p = 0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10–1.58, p = 0.19).
These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs <2 mm.
Arsen Osipov, Nicholas Nissen, Joanne Rutgers, Deepti Dhall, Jason Naziri, Shefali Chopra, Quanlin Li, and Andrew Eugene Hendifar have nothing to disclose.
- 2.SEER Cancer Statistics Review. National Cancer Institute; 1975–2013. http://seer.cancer.gov/csr/1975_2013/. Accessed 9 Jan 2016.
- 9.Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782-774.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.College of American Pathologists. Protocol for the Examination of Specimens From Patients With Carcinoma of the Exocrine Pancreas. 2013; http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/PancreasExo_13protocol_3201.pdf. Accessed December 11, 2016.
- 24.Nitta T, Nakamura T, Mitsuhashi T, Asano T, Okamura K, Tsuchikawa T et al. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Surg Today. 2016;47(4): 490-497.CrossRefPubMedGoogle Scholar
- 25.Pathologists TRCo. The Royal College of Pathologists. Standards and Minimum Datasets for Reporting Cancers. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. London 2002.Google Scholar
- 27.Sobin LH GM, Wittekind C (2009) International Union Against Cancer TNM classification of malignant tumours. 7th edWiley-Blackwell, Oxford.Google Scholar
- 31.John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R et al. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford). 2013;15(9):674–80.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Fernandez-del Castillo C, Deshpande V et al. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg. 2013;257(4):731–36.CrossRefPubMedGoogle Scholar
- 41.Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259(4):656–64.CrossRefPubMedGoogle Scholar
- 43.Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503–10.CrossRefPubMedPubMedCentralGoogle Scholar